全文获取类型
收费全文 | 158828篇 |
免费 | 10790篇 |
国内免费 | 625篇 |
专业分类
耳鼻咽喉 | 1769篇 |
儿科学 | 3905篇 |
妇产科学 | 2617篇 |
基础医学 | 20953篇 |
口腔科学 | 3389篇 |
临床医学 | 15561篇 |
内科学 | 33647篇 |
皮肤病学 | 3242篇 |
神经病学 | 14607篇 |
特种医学 | 6971篇 |
外国民族医学 | 14篇 |
外科学 | 25229篇 |
综合类 | 1957篇 |
一般理论 | 109篇 |
预防医学 | 11818篇 |
眼科学 | 3306篇 |
药学 | 10145篇 |
中国医学 | 238篇 |
肿瘤学 | 10766篇 |
出版年
2023年 | 885篇 |
2022年 | 1485篇 |
2021年 | 3375篇 |
2020年 | 2079篇 |
2019年 | 3118篇 |
2018年 | 3591篇 |
2017年 | 2800篇 |
2016年 | 3137篇 |
2015年 | 3587篇 |
2014年 | 5092篇 |
2013年 | 6851篇 |
2012年 | 10338篇 |
2011年 | 11007篇 |
2010年 | 6308篇 |
2009年 | 6014篇 |
2008年 | 9751篇 |
2007年 | 10190篇 |
2006年 | 10098篇 |
2005年 | 10148篇 |
2004年 | 9314篇 |
2003年 | 8627篇 |
2002年 | 8274篇 |
2001年 | 2154篇 |
2000年 | 1846篇 |
1999年 | 2127篇 |
1998年 | 1926篇 |
1997年 | 1554篇 |
1996年 | 1334篇 |
1995年 | 1251篇 |
1994年 | 1126篇 |
1993年 | 1015篇 |
1992年 | 1292篇 |
1991年 | 1192篇 |
1990年 | 1032篇 |
1989年 | 973篇 |
1988年 | 911篇 |
1987年 | 884篇 |
1986年 | 886篇 |
1985年 | 865篇 |
1984年 | 925篇 |
1983年 | 796篇 |
1982年 | 960篇 |
1981年 | 860篇 |
1980年 | 728篇 |
1979年 | 654篇 |
1978年 | 646篇 |
1977年 | 534篇 |
1976年 | 514篇 |
1974年 | 512篇 |
1973年 | 449篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Ronald Martin Jaime Williams Thomas Hadjistavropoulos Heather D Hadjistavropoulos Michael MacLean 《Revue canadienne de recherche en sciences infirmières》2005,37(2):142-164
The literature suggests that pain in the elderly, especially among seniors with dementia, is under-assessed and under-treated.This qualitative study solicited the perspectives of seniors, front-line nursing staff, nursing-home administrators, and informal caregivers of seniors with dementia on the current status of pain assessment and management. The views of these participants complement the research findings reported in the literature. While some of their explanations and potential solutions concerning under-treatment of pain in seniors echo views that have been presented in the literature, the participants also pointed to factors and avenues that have been given less formal consideration (e.g., systemic barriers to effective assessment and treatment of pain).They also highlighted the need for pain-control strategies beyond medication. The implications of these findings are discussed. 相似文献
32.
33.
Treatment of thrombocytopenia with alfa interferon 总被引:1,自引:0,他引:1
A M Lever M G Brook I Yap H C Thomas 《British medical journal (Clinical research ed.)》1987,295(6612):1519-1520
34.
Trawat Attarbaschi Julia Sacher Thomas Geiss-Granadia Nikolas Klein Nilufar Mossaheb Rupert Lanzenberger Susanne Asenbaum Robert Dudczak Siegfried Kasper Johannes Tauscher 《European neuropsychopharmacology》2007,17(2):102-107
We explored the relationship between striatal dopamine-2 (D(2)) receptor occupancy and extra-pyramidal symptoms (EPS) in bipolar patients receiving olanzapine. Seventeen patients with a DSM-IV diagnosis of bipolar disorder were treated with 5-45 mg/day olanzapine for at least 14 days. After that period, D(2) receptor occupancy was determined using Iodobenzamide (IBZM) and SPECT. EPS were assessed by the Simpson-Angus Scale (SAS) and Barnes-Akathisia Scale (BAS). We found a dose-dependent increase in occupancy: 5 mg led to 28-50%, 10 mg to 40-68%, 15 mg to 69%, 20 mg to 57-66%, 30 mg to 66% and 45 mg to 80% D(2) receptor occupancy; and a significant correlation between plasma levels and occupancy (R(2)=.55, P=.001). Similar to schizophrenic patients, bipolar patients did not exhibit EPS at D(2) occupancy levels of 28 to 80%. Although we did not find an increased vulnerability for acute EPS in bipolar patients receiving olanzapine at clinical relevant doses, this needs to be replicated with larger sample sizes. 相似文献
35.
Regula E Egli Thomas L Kash Kevin Choo Valentina Savchenko Robert T Matthews Randy D Blakely Danny G Winder 《Neuropsychopharmacology》2005,30(4):657-668
The bed nucleus of the stria terminalis (BNST) and its adrenergic input are key components in stress-induced reinstatement and maintenance of drug use. Intra-BNST injections of either beta-adrenergic receptor (beta-AR) antagonists or alpha2-adrenergic receptor (alpha2-AR) agonists can inhibit footshock-induced reinstatement and maintenance of cocaine- and morphine-seeking. Using electrophysiological recording methods in an in vitro slice preparation from C57/Bl6j adult male mouse BNST, we have examined the effects of adrenergic receptor activation on excitatory synaptic transmission in the lateral dorsal supracommissural BNST (dBNST) and subcommissural BNST (vBNST). Alpha2-AR activation via UK-14,304 (10 microM) results in a decrease in excitatory transmission in both dBNST and vBNST, an effect predominantly dependent upon the alpha2A-AR subtype. Beta-AR activation via isoproterenol (1 microM) results in an increase in excitatory transmission in dBNST, but not in vBNST. Consistent with the work with receptor subtype specific agonists, application of the endogenous ligand norepinephrine (NE, 100 microM) elicits two distinct effects on glutamatergic transmission. In dBNST, NE elicits an increase in transmission (62% of dBNST NE experiments) or a decrease in transmission (38% of dBNST NE experiments). In vBNST, NE elicits a decrease in transmission in 100% of the experiments. In dBNST, the NE-induced increase in synaptic transmission is blocked by beta1/beta2- and beta2-, but not beta1-specific antagonists. In addition, this increase is also reduced by the alpha2-AR antagonist yohimbine and is absent in the alpha2A-AR knockout mouse. In vBNST, the NE-induced decrease in synaptic transmission is markedly reduced in the alpha2A-AR knockout mouse. Further experiments demonstrate that the actions of NE on glutamatergic transmission can be correlated with beta-AR function. 相似文献
36.
Yubin Miao Said D Figueroa Darrell R Fisher Herbert A Moore Richard F Testa Timothy J Hoffman Thomas P Quinn 《Journal of nuclear medicine》2008,49(5):823-829
Peptide-targeted alpha-therapy with 7.4 MBq of (212)Pb-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-ReO-[Cys(3,4,10),d-Phe(7),Arg(11)]alpha-MSH(3-13) ((212)Pb-DOTA-Re(Arg(11))CCMSH) cured 45% of B16/F1 murine melanoma-bearing C57 mice in a 120-d study, highlighting its melanoma treatment potential. However, there is a need to develop an imaging surrogate for patient-specific dosimetry and to monitor the tumor response to (212)Pb-DOTA-Re(Arg(11))CCMSH therapy. The purpose of this study was to evaluate the potential of (203)Pb-DOTA-Re(Arg(11))CCMSH as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH. METHODS: DOTA-Re(Arg(11))CCMSH was labeled with (203)Pb in 0.5 M NH(4)OAc buffer at pH 5.4. The internalization and efflux of (203)Pb-DOTA-Re(Arg(11))CCMSH were determined in B16/F1 melanoma cells. The pharmacokinetics of (203)Pb-DOTA-Re(Arg(11))CCMSH was examined in B16/F1 melanoma-bearing C57 mice. A micro-SPECT/CT study was performed with (203)Pb-DOTA-Re(Arg(11))CCMSH in a B16/F1 melanoma-bearing C57 mouse at 2 h after injection. RESULTS: (203)Pb-DOTA-Re(Arg(11))CCMSH was easily prepared in NH(4)OAc buffer and completely separated from the excess nonradiolabeled peptide by reversed-phase high-performance liquid chromatography (RP-HPLC). (203)Pb-DOTA-Re(Arg(11))CCMSH displayed fast internalization and extended retention in B16/F1 cells. Approximately 73% of (203)Pb-DOTA-Re(Arg(11))CCMSH activity internalized after a 20-min incubation at 25 degrees C. After incubation of the cells in culture medium for 20 min, 78% of internalized activity remained in the cells. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a biodistribution pattern similar to that of (212)Pb-DOTA-Re(Arg(11))CCMSH in B16/F1 melanoma-bearing mice. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor uptake of 12.00+/-3.20 percentage injected dose per gram (%ID/g) at 1 h after injection. The tumor uptake gradually decreased to 3.43+/-1.12 %ID/g at 48 h after injection. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor-to-kidney uptake ratio of 1.53 at 2 h after injection. The absorbed doses to the tumor and kidneys were 4.32 and 4.35 Gy, respectively, per 37 MBq. Whole-body clearance of (203)Pb-DOTA-Re(Arg(11))CCMSH was fast, with approximately 89% of the injected activity cleared through the urinary system by 2 h after injection. (203)Pb showed 1.6-mm SPECT resolution, which was comparable to (99m)Tc. Melanoma lesions were visualized through SPECT/CT images of (203)Pb-DOTA-Re(Arg(11))CCMSH at 2 h after injection. CONCLUSION: (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited favorable pharmacokinetic and tumor imaging properties, highlighting its potential as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH melanoma treatment. 相似文献
37.
38.
39.
Michael Hermansson Anders Ekedahl Jonas Ranstam Thomas Zilling 《BMC gastroenterology》2009,9(1):25-13
Background
Despite a decreasing incidence of peptic ulcer disease, most previous studies report a stabile incidence of ulcer complications. We wanted to investigate the incidence of peptic ulcer complications in Sweden before and after the introduction of the proton pump inhibitors (PPI) in 1988 and compare these data to the sales of non-steroid anti-inflammatory drugs (NSAID) and acetylsalicylic acid (ASA). 相似文献40.
Parastoo Jangouk Thomas Dehmel Gerd Meyer Zu Hörste Andreas Ludwig Helmar C. Lehmann Bernd C. Kieseier 《Glia》2009,57(16):1765-1774
The disintegrin and metalloproteinase 10 (ADAM10) is a membrane‐anchored metalloproteinase with both proteolytic and disintegrin characteristics. Here, we investigate the expression, regulation, and functional role of ADAM10 in axonal outgrowth and myelination of the peripheral nerve. Expression pattern analysis of 11 ADAM family members in co‐cultures of rat dorsal root ganglia (DRG) neurons and Schwann cells (SCs) demonstrated the most pronounced mRNA expression for ADAM10. In further studies, ADAM10 was found to be consistently upregulated in DRG‐SC co‐cultures before the induction of myelination. Neurons as well as SCs widely expressed ADAM10 at the protein level. In neurons, the expression of ADAM10 was exclusively limited to the axons before the induction of myelination. Inhibition of ADAM10 activity by the hydroxamate‐based inhibitors GI254023X and GW280264X resulted in a significant decrease in the mean axonal length. These data suggest that ADAM10 represents a prerequisite for myelination, although its activity is not required during the process of myelination itself as demonstrated by expression analysis of myelin protein zero (P0) and Sudan black staining. Hence, during the process of myelin formation, ADAM10 is highly upregulated and appears to be critically involved in axonal outgrowth that is a requirement for myelination in the peripheral nerve. © 2009 Wiley‐Liss, Inc. 相似文献